Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis

What Was Tested

Researchers studied Teriparatide in this controlled clinical trial publication.

Bone anabolic effects of TPTD in postmenopausal women with osteoporosis may be blunted during the initial phase after switching from ALN to TPTD.

To explore the long-term implications, the researchers examined histomorphometric and biochemical markers of bone turnover of patients on TPTD therapy after long-term ALN treatment.

Who Took Part

The abstract describes 16 patients taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, women only.

Paired biopsies were obtained after tetracycline double labeling at baseline and after 24 months of TPTD treatment from 29 ALN-pretreated (64.5 ± 16.4 months) and 16 TN patients.

Biochemical markers were measured at baseline, during the treatment, or at study end.

How the Study Was Run

A time span of 24 months appears in the methods.

What Was Measured

PubMed files the paper under topics including Alendronate, Biomarkers, Biopsy, Bone Density, Bone Density Conservation Agents, Bone Remodeling and Drug Substitution.

What This Means in Plain Language

This is a controlled clinical trial of Teriparatide in 16 patients over 24 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Teriparatide compound page, all human trials.